Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393978 · ClinicalTrials.gov registry record · Phase 4
Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania
A Phase 4 study of Bipolar Disorder and Cannabis-Related Disorder, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00393978 is a Phase 4 study of Bipolar Disorder and Cannabis-Related Disorder that has completed, run by University of Cincinnati. The registered enrollment target is 75 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00393978, a Phase 4 study of Bipolar Disorder and Cannabis-Related Disorder, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.
Conditions Studied
Interventions
- DRUG Quetiapine and placebo
- DRUG Quetiapine and Topiramate
Study Locations (1)
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-11 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00393978
The ClinicalTrials.gov registry entry for NCT00393978 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (77% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Quetiapine and placebo is the first listed.
NCT00393978 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00393978 about?
NCT00393978 is a clinical study titled "Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania". The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.
What is the current status of trial NCT00393978?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2006-11. Estimated completion is 2014-03.
What conditions does trial NCT00393978 study?
This clinical trial studies the following conditions: Bipolar Disorder, Cannabis-Related Disorder.
What interventions are being tested in trial NCT00393978?
The interventions under investigation include: Quetiapine and placebo (DRUG), Quetiapine and Topiramate (DRUG).
Who is sponsoring clinical trial NCT00393978?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00393978 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
COMPLETED · Phase 4
-
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
COMPLETED · Phase 4
-
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
COMPLETED · Phase 4
-
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
COMPLETED · Phase 4
-
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.